tigeR: Tumor immunotherapy gene expression data analysis R package

Abstract

Immunotherapy shows great promise for treating advanced cancers, but its effectiveness varies widely among different patients and cancer types. Identifying biomarkers and developing robust predictive models to discern which patients are most likely to benefit from immunotherapy is of great importance. In this context, we have developed the tumor immunotherapy gene expression R package (tigeR 1.0) to address the increasing need for effective tools to explore biomarkers and construct predictive models. tigeR encompasses four distinct yet closely interconnected modules. The Biomarker Evaluation module enables researchers to evaluate whether the biomarkers of interest are associated with immunotherapy response via built-in or custom immunotherapy gene expression data. The Tumor Microenvironment Deconvolution module integrates 10 open-source algorithms to obtain the proportions of different cell types within the tumor microenvironment, facilitating the investigation of the association between immune cell populations and immunotherapy response. The Prediction Model Construction module equips users with the ability to construct sophisticated prediction models using a range of built-in machine-learning algorithms. The Response Prediction module predicts the immunotherapy response for the patients from gene expression data using our pretrained machine learning models or public gene expression signatures. By providing these diverse functionalities, tigeR aims to simplify the process of analyzing immunotherapy gene expression data, thus making it accessible to researchers without advanced programming skills. The source code and example for the tigeR project can be accessed at http://github.com/YuLab-SMU/tigeR.

Keywords

gene expression / machine learning / R package / tumor immunotherapy / tumor microenvironment

References

[1] Wang, Yun, Min Wang, Hao-Xiang Wu, and Rui-Hua Xu. 2021. “Advancing to the Era of Cancer Immunotherapy.” Cancer Communications 41: 803-829. https://doi.org/10.1002/cac2.12178

[2] Hodi, F. Stephen, Steven J. O'Day, David F. McDermott, Robert W. Weber, Jeffrey A. Sosman, John B. Haanen, Rene Gonzalez, et al. 2010. “Improved Survival With Ipilimumab in Patients With Metastatic Melanoma.” New England Journal of Medicine 363: 711-723. https://doi.org/10.1056/NEJMoa1003466

[3] Eggermont, Alexander M. M., Christian U. Blank, Mario Mandala, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, et al. 2018. “Adjuvant Pembrolizumab Versus Placebo in Resected Stage III Melanoma.” New England Journal of Medicine 378: 1789-1801. https://doi.org/10.1056/NEJMoa1802357

[4] Vaddepally, Raju K., Prakash Kharel, Ramesh Pandey, Rohan Garje, and Abhinav B. Chandra. 2020. “Review of Indications of FDA-Approved Immune Checkpoint Inhibitors Per NCCN Guidelines With the Level of Evidence.” Cancers 12: 738. https://doi.org/10.3390/cancers12030738

[5] van Weverwijk, Antoinette, and Karin E. de Visser. 2023. “Mechanisms Driving the Immunoregulatory Function of Cancer Cells.” Nature Reviews Cancer 23: 193-215. https://doi.org/10.1038/s41568-022-00544-4

[6] Sharma, Padmanee, Bilal A. Siddiqui, Swetha Anandhan, Shalini S. Yadav, Sumit K. Subudhi, Jianjun Gao, Sangeeta Goswami, and James P. Allison. 2021. “The Next Decade of Immune Checkpoint Therapy.” Cancer Discovery 11: 838-857. https://doi.org/10.1158/2159-8290.Cd-20-1680

[7] Jia, Qingzhu, Aoyun Wang, Yixiao Yuan, Bo Zhu, and Haixia Long. 2022. “Heterogeneity of the Tumor Immune Microenvironment and Its Clinical Relevance.” Experimental Hematology & Oncology 11: 24. https://doi.org/10.1186/s40164-022-00277-y

[8] Reuter, Jason A., Damek V. Spacek, and Michael P. Snyder. 2015. “High-Throughput Sequencing Technologies.” Molecular Cell 58: 586-597. https://doi.org/10.1016/j.molcel.2015.05.004

[9] Stark, Rory, Marta Grzelak, and James Hadfield. 2019. “RNA Sequencing: The Teenage Years.” Nature Reviews Genetics 20: 631-656. https://doi.org/10.1038/s41576-019-0150-2

[10] Hong, Mingye, Shuang Tao, Ling Zhang, Li-Ting Diao, Xuanmei Huang, Shaohui Huang, Shu-Juan Xie, Zhen-Dong Xiao, and Hua Zhang. 2020. “RNA Sequencing: New Technologies and Applications in Cancer Research.” Journal of Hematology & Oncology 13: 166. https://doi.org/10.1186/s13045-020-01005-x

[11] Gentles, Andrew J., Aaron M. Newman, Chih Long Liu, Scott V. Bratman, Weiguo Feng, Dongkyoon Kim, Viswam S. Nair, et al. 2015. “The Prognostic Landscape of Genes and Infiltrating Immune Cells Across Human Cancers.” Nature Medicine 21: 938-945. https://doi.org/10.1038/nm.3909

[12] Li, Binghua, Yunzheng Li, Huajun Zhou, Yanchao Xu, Yajuan Cao, Chunxiao Cheng, Jin Peng, et al. 2024. “Multiomics Identifies Metabolic Subtypes Based on Fatty Acid Degradation Allocating Personalized Treatment in Hepatocellular Carcinoma.” Hepatology 79: 289-306. https://doi.org/10.1097/hep.0000000000000553

[13] Liu, Wei, Lei Xie, Yao-Hui He, Zhi-Yong Wu, Lu-Xin Liu, Xue-Feng Bai, Dan-Xia Deng, et al. 2021. “Large-Scale and High-Resolution Mass Spectrometry-Based Proteomics Profiling Defines Molecular Subtypes of Esophageal Cancer for Therapeutic Targeting.” Nature Communications 12: 4961. https://doi.org/10.1038/s41467-021-25202-5

[14] Jin, Xi, Yi-Fan Zhou, Ding Ma, Shen Zhao, Cai-Jin Lin, Yi Xiao, Tong Fu, et al. 2023. “Molecular Classification of Hormone Receptor-Positive HER2-Negative Breast Cancer.” Nature Genetics 55: 1696-1708. https://doi.org/10.1038/s41588-023-01507-7

[15] Katipally, Rohan R., Carlos A. Martinez, Siân A. Pugh, John A. Bridgewater, John N. Primrose, Enric Domingo, Timothy S. Maughan, et al. 2023. “Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial.” JAMA Oncology 9: 1245-1254. https://doi.org/10.1001/jamaoncol.2023.2535

[16] Lin, Yilin, Xiaoxian Pan, Long Zhao, Changjiang Yang, Zhen Zhang, Bo Wang, Zhidong Gao, et al. 2021. “Immune Cell Infiltration Signatures Identified Molecular Subtypes and Underlying Mechanisms in Gastric Cancer.” npj Genomic Medicine 6: 83. https://doi.org/10.1038/s41525-021-00249-x

[17] Jiang, Peng, Shengqing Gu, Deng Pan, Jingxin Fu, Avinash Sahu, Xihao Hu, Ziyi Li, et al. 2018. “Signatures of T Cell Dysfunction and Exclusion Predict Cancer Immunotherapy Response.” Nature Medicine 24: 1550-1558. https://doi.org/10.1038/s41591-018-0136-1

[18] Li, Taiwen, Jingxin Fu, Zexian Zeng, David Cohen, Jing Li, Qianming Chen, Bo Li, and X Shirley Liu. 2020. “TIMER2.0 for Analysis of Tumor-Infiltrating Immune Cells.” Nucleic Acids Research 48: W509-W514. https://doi.org/10.1093/nar/gkaa407

[19] Chen, Li, Tianjian Chen, Ya Zhang, Haichen Lin, Ruihan Wang, Yihang Wang, Hongyu Li, et al. 2022. “TIRSF: A Web Server for Screening Gene Signatures to Predict Tumor Immunotherapy Response.” Nucleic Acids Research 50: W761-W767. https://doi.org/10.1093/nar/gkac374

[20] Chen, Zhihang, Ziwei Luo, Di Zhang, Huiqin Li, Xuefei Liu, Kaiyu Zhu, Hongwan Zhang, et al 2023. “TIGER: A Web Portal of Tumor Immunotherapy Gene Expression Resource.” Genomics, Proteomics & Bioinformatics 21: 337-348. https://doi.org/10.1016/j.gpb.2022.08.004

[21] Newman, Aaron M., Chih Long Liu, Michael R. Green, Andrew J. Gentles, Weiguo Feng, Yue Xu, Chuong D. Hoang, Maximilian Diehn, and Ash A. Alizadeh. 2015. “Robust Enumeration of Cell Subsets from Tissue Expression Profiles.” Nature Methods 12: 453-457. https://doi.org/10.1038/nmeth.3337

[22] Li, Taiwen, Jingyu Fan, Binbin Wang, Nicole Traugh, Qianming Chen, Jun S. Liu, Bo Li, and X. Shirley Liu. 2017. “TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells.” Cancer Research 77: e108-e110. https://doi.org/10.1158/0008-5472.Can-17-0307

[23] Yoshihara, Kosuke, Maria Shahmoradgoli, Emmanuel Martínez, Rahulsimham Vegesna, Hoon Kim, Wandaliz Torres-Garcia, Victor Treviño, et al. 2013. “Inferring Tumour Purity and Stromal and Immune Cell Admixture From Expression Data.” Nature Communications 4: 2612. https://doi.org/10.1038/ncomms3612

[24] Charoentong, Pornpimol, Francesca Finotello, Mihaela Angelova, Clemens Mayer, Mirjana Efremova, Dietmar Rieder, Hubert Hackl, and Zlatko Trajanoski. 2017. “Pan-Cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade.” Cell Reports 18: 248-262. https://doi.org/10.1016/j.celrep.2016.12.019

[25] Aran, Dvir, Zicheng Hu, and Atul J. Butte. 2017. “Xcell: Digitally Portraying the Tissue Cellular Heterogeneity Landscape.” Genome Biology 18: 220. https://doi.org/10.1186/s13059-017-1349-1

[26] Racle, Julien, Kaat de Jonge, Petra Baumgaertner, Daniel E. Speiser, and David Gfeller. 2017. “Simultaneous Enumeration of Cancer and Immune Cell Types From Bulk Tumor Gene Expression Data.” Elife 6: e26476. https://doi.org/10.7554/eLife.26476

[27] Jiménez-Sánchez, Alejandro, Oliver Cast, and Martin L. Miller. 2019. “Comprehensive Benchmarking and Integration of Tumor Microenvironment Cell Estimation Methods.” Cancer Research 79: 6238-6246. https://doi.org/10.1158/0008-5472.Can-18-3560

[28] Monaco, Gianni, Bernett Lee, Weili Xu, Seri Mustafah, You Yi Hwang, Christophe Carré, Nicolas Burdin, et al. 2019. “RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell Types.” Cell Reports 26: 1627-1640.e7. https://doi.org/10.1016/j.celrep.2019.01.041

[29] Finotello, Francesca, Clemens Mayer, Christina Plattner, Gerhard Laschober, Dietmar Rieder, Hubert Hackl, Anne Krogsdam, et al. 2019. “Molecular and Pharmacological Modulators of the Tumor Immune Contexture Revealed by Deconvolution of RNA-seq Data.” Genome Medicine 11: 34. https://doi.org/10.1186/s13073-019-0638-6

[30] Becht, Etienne, Nicolas A. Giraldo, Laetitia Lacroix, Bénédicte Buttard, Nabila Elarouci, Florent Petitprez, Janick Selves, et al. 2016. “Estimating the Population Abundance of Tissue-Infiltrating Immune and Stromal Cell Populations Using Gene Expression.” Genome Biology 17: 218. https://doi.org/10.1186/s13059-016-1070-5

[31] Liu, Baolin, Yuanyuan Zhang, Dongfang Wang, Xueda Hu, and Zemin Zhang. 2022. “Single-Cell Meta-Analyses Reveal Responses of Tumor-Reactive CXCL13⁺ T Cells to Immune-Checkpoint Blockade.” Nature Cancer 3: 1123-1136. https://doi.org/10.1038/s43018-022-00433-7

[32] Yang, Moran, Jiaqi Lu, Guodong Zhang, Yiying Wang, Mengdi He, Qing Xu, Congjian Xu, and Haiou Liu. 2021. “CXCL13 Shapes Immunoactive Tumor Microenvironment and Enhances the Efficacy of PD-1 Checkpoint Blockade in High-Grade Serous Ovarian Cancer.” Journal for ImmunoTherapy of Cancer 9: e001136. https://doi.org/10.1136/jitc-2020-001136

[33] Cohen, Merav, Amir Giladi, Oren Barboy, Pauline Hamon, Baoguo Li, Mor Zada, Anna Gurevich-Shapiro, et al. 2022. “The Interaction of CD4⁺ Helper T Cells With Dendritic Cells Shapes the Tumor Microenvironment and Immune Checkpoint Blockade Response.” Nature Cancer 3: 303-317. https://doi.org/10.1038/s43018-022-00338-5

[34] Gide, Tuba N., Camelia Quek, Alexander M. Menzies, Annie T. Tasker, Ping Shang, Jeff Holst, Jason Madore, et al. 2019. “Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.” Cancer Cell 35: 238-255.e6. https://doi.org/10.1016/j.ccell.2019.01.003

[35] Prat, Aleix, Alejandro Navarro, Laia Paré, Noemí Reguart, Patricia Galván, Tomás Pascual, Alex Martínez, et al. 2017. “Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.” Cancer Research 77: 3540-3550. https://doi.org/10.1158/0008-5472.Can-16-3556

[36] Cabrita, Rita, Martin Lauss, Adriana Sanna, Marco Donia, Mathilde Skaarup Larsen, Shamik Mitra, Iva Johansson, et al. 2020. “Tertiary Lymphoid Structures Improve Immunotherapy and Survival in Melanoma.” Nature 577: 561-565. https://doi.org/10.1038/s41586-019-1914-8

[37] Amato, Carol M., Jennifer D. Hintzsche, Keith Wells, Allison Applegate, Nicholas T. Gorden, Victoria M. Vorwald, Richard P. Tobin, et al. 2020. “Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy.” Cancers 12: 1943. https://doi.org/10.3390/cancers12071943. https://www.mdpi.com/2072-6694/12/7/1943

[38] Hugo, Willy, Jesse M. Zaretsky, Lu Sun, Chunying Song, Blanca Homet Moreno, Siwen Hu-Lieskovan, Beata Berent-Maoz, et al. 2016. “Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.” Cell 165: 35-44. https://doi.org/10.1016/j.cell.2016.02.065

[39] Riaz, Nadeem, Jonathan J. Havel, Vladimir Makarov, Alexis Desrichard, Walter J. Urba, Jennifer S. Sims, F. Stephen Hodi, et al. 2017. “Tumor and Microenvironment Evolution During Immunotherapy With Nivolumab.” Cell 171: 934-949.e16. https://doi.org/10.1016/j.cell.2017.09.028

[40] Newman, Aaron M., Chloé B. Steen, Chih Long Liu, Andrew J. Gentles, Aadel A. Chaudhuri, Florian Scherer, Michael S. Khodadoust, et al. 2019. “Determining Cell Type Abundance and Expression From Bulk Tissues With Digital Cytometry.” Nature Biotechnology 37: 773-782. https://doi.org/10.1038/s41587-019-0114-2

[41] Van Allen, Eliezer M., Diana Miao, Bastian Schilling, Sachet A. Shukla, Christian Blank, Lisa Zimmer, Antje Sucker, et al. 2015. “Genomic Correlates of Response to CTLA-4 Blockade in Metastatic Melanoma.” Science 350: 207-211. https://doi.org/10.1126/science.aad0095

[42] Nathanson, Tavi, Arun Ahuja, Alexander Rubinsteyn, Bulent Arman Aksoy, Matthew D. Hellmann, Diana Miao, Eliezer Van Allen, et al. 2017. “Somatic Mutations and Neoepitope Homology in Melanomas Treated With CTLA-4 Blockade.” Cancer Immunology Research 5: 84-91. https://doi.org/10.1158/2326-6066.Cir-16-0019

[43] Yang, Mei, Ya-Ru Miao, Gui-Yan Xie, Mei Luo, Hui Hu, Hang Fai Kwok, Jian Feng, and An-Yuan Guo. 2022. “ICBatlas: A Comprehensive Resource for Depicting Immune Checkpoint Blockade Therapy Characteristics From Transcriptome Profiles.” Cancer Immunology Research 10: 1398-1406. https://doi.org/10.1158/2326-6066.Cir-22-0249

[44] Ru, Beibei, Ching Ngar Wong, Yin Tong, Jia Yi Zhong, Sophia Shek Wa Zhong, Wai Chung Wu, Ka Chi Chu, et al. 2019. “TISIDB: an Integrated Repository Portal for Tumor-Immune System Interactions.” Bioinformatics 35: 4200-4202. https://doi.org/10.1093/bioinformatics/btz210

[45] Zeng, Dongqiang, Yiran Fang, Peng Luo, Wenjun Qiu, Shixiang Wang, Rongfang Shen, Wenchao Gu, et al. 2024. “IOBR2: Multidimensional Decoding Tumor Microenvironment for Immuno-Oncology Research.” bioRxiv 2024. https://doi.org/10.1101/2024.01.13.575484

[46] Lapuente-Santana, Óscar, Maisa van Genderen, Peter A. J. Hilbers, Francesca Finotello, and Federica Eduati. 2021. “Interpretable Systems Biomarkers Predict Response to Immune-Checkpoint Inhibitors.” Patterns 2: 100293. https://doi.org/10.1016/j.patter.2021.100293

[47] Huber, Wolfgang, Vincent J. Carey, Robert Gentleman, Simon Anders, Marc Carlson, Benilton S. Carvalho, Hector Corrada Bravo, et al. 2015. “Orchestrating High-Throughput Genomic Analysis With Bioconductor.” Nature Methods 12: 115-121. https://doi.org/10.1038/nmeth.3252

RIGHTS & PERMISSIONS

2024 The Author(s). iMeta published by John Wiley & Sons Australia, Ltd on behalf of iMeta Science.